Wake Forest Baptist - Comprehensive Cancer Center

Atrium Health

Winston-Salem, NC

Sorting 10 by

Accepting patients

EXCALIBER - Maintenance

Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma
  • CELMoD
  • Randomization
  • Post-Autologous Stem Cell Transplant
  • Phase 3

Accepting patients

MajesTEC-7

A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
  • Bispecific Antibody
  • BCMA
  • Randomization
  • Phase 3
  • Has results

Accepting patients

Etentamig

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • Phase 1
  • Has results

Accepting patients

Linvoseltamab

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
  • Bispecific Antibody
  • BCMA
  • Phase 1
  • Has results

Not currently accepting

Iberdomide vs. Observation Post Ide-Cel CAR-T

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
  • CELMoD
  • Maintenance
  • Randomization
  • Phase 2

Accepting patients

DoMMino-1

A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
  • Bromodomain Inhibitor
  • CBP (CREB-binding Protein) Inhibitor
  • P300 Inhibitor
  • Phase 2

Accepting patients

Etentamig (ABBV-383)

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects With Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • Phase 1/2

Accepting patients

Patient Registry: Undergoing Stem Cell Transplant

The Prospective Collection, Storage and Reporting of Data on Patients
  • Patient Registry
  • Observational Trial

Accepting patients

Surzetoclax (ABBV-453)

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma
  • BCL-2 Inhibitor
  • Phase 1/2

Accepting patients

IDP-023

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
  • Natural Killer Cells (Allogeneic)
  • Phase 1/2